Literature DB >> 2467767

A rat model of captopril immunogenicity.

A L Foster1, J W Coleman.   

Abstract

Following chronic administration of the protein-reactive sulphydryl drug captopril (CP) to rats, an IgG antibody response to CP-derived antigen was detected by ELISA in rats administered the free drug at doses of 270 mumol/kg (i.p. and i.m.) and 27 mumol/kg (i.p.). The antibody response was slow to develop, requiring three series of four daily injections at one-monthly intervals before CP-specific serum IgG was apparent. The IgG antibody recognized CP-ovalbumin but not ovalbumin, and was inhibited by CP in protein-conjugated form, and by free CP and CP-disulphide, thus confirming specificity for a CP-derived antigenic determinant. A drug-induced non-drug-specific IgG response directed against human serum albumin was also observed after chronic high dose CP treatment. No IgG anti-DNA, IgM anti-CP nor IgM anti-HSA responses were seen following chronic drug administration. These studies show that CP, like the model reactive metabolite dinitrofluorobenzene, but unlike other protein-reactive drugs such as D-penicillamine and benzylpenicillin, is immunogenic in the rat. The findings also suggest the possibility that anti-CP antibodies reported in man may be drug-induced, rather than naturally occurring.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467767      PMCID: PMC1541848     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Immune-complex glomerulopathy in patients treated with captopril.

Authors:  S J Hoorntje; C G Kallenberg; J J Weening; A J Donker; T H The; P J Hoedemaeker
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

Review 2.  Angiotensin-converting enzyme inhibitors: past, present, and bright future.

Authors:  C R Edwards; P L Padfield
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

3.  Drug-protein conjugates--XVII. The effect of storage on the antigenicity and immunogenicity of benzylpenicillin in the rat.

Authors:  G Christie; J W Coleman; B K Park
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

4.  In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans.

Authors:  K K Wong; S Lan; B H Migdalof
Journal:  Biochem Pharmacol       Date:  1981-10-01       Impact factor: 5.858

5.  Drug protein conjugates--I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat.

Authors:  B K Park; P S Grabowski; J H Yeung; A M Breckenridge
Journal:  Biochem Pharmacol       Date:  1982-05-01       Impact factor: 5.858

6.  Captopril(SQ 14,225): in vitro and in vivo influence on the proliferative response of rat lymphocytes.

Authors:  L Binderup; E Bramm; E Arrigoni-Martelli
Journal:  Experientia       Date:  1982-03-15

7.  Antinuclear and antinative DNA antibodies during captopril treatment.

Authors:  C G Kallenberg; S J Hoorntje; A J Smit; J J Weening; A J Donker; P H Hoedemaeker; T H The
Journal:  Acta Med Scand       Date:  1982

8.  Cutaneous reactions to captopril. Predictive value of skin tests.

Authors:  A J Smit; S Van der Laan; J De Monchy; C G Kallenberg; A J Donker
Journal:  Clin Allergy       Date:  1984-09

9.  Captopril and immune regulation.

Authors:  J F Delfraissy; P Galanaud; J F Balavoine; C Wallon; J Dormont
Journal:  Kidney Int       Date:  1984-06       Impact factor: 10.612

10.  Drug-protein conjugates--IX. Immunogenicity of captopril-protein conjugates.

Authors:  J H Yeung; J W Coleman; B K Park
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.